Literature DB >> 22209163

Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice.

Irina Caminschi1, David Vremec, Fatma Ahmet, Mireille H Lahoud, Jose A Villadangos, Kenneth M Murphy, William R Heath, Ken Shortman.   

Abstract

Injection of antigens coupled to antibodies against the dendritic cell (DC) surface molecule Clec9A has been shown to produce strongly enhanced antibody responses even without co-administration of adjuvants, via antigen presentation by DC on MHC class II and consequent production of follicular helper T cells. A series of mutant mice were tested to determine the DC subtypes responsible for this MHC II presentation of targeted antigen, compared to presentation of antigen on MHC I. A new clec9A null mouse was developed; these mice did not give enhanced antibody production, confirming the response was dependent on Clec9A-expressing DC. However targeting of antigen to Clec9A in batf3 null mice produced enhanced antibody responses despite the marked reduction in CD8(+) DC, the major Clec9A-expressing DC subtype. This was shown to be dependent on efficient MHC II presentation by minor Clec9A-expressing DC subtypes in the environment of the Batf3(-/-) mice, namely early cells of the CD8 DC lineage and the plasmacytoid-related CD8(+) DC subset, but not by plasmacytoid cells themselves. However in normal mice most MHC II presentation of the Clec9A-targeted antigen was by the major CD8(+) DC population, the DC also responsible for presentation on MHC I.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209163     DOI: 10.1016/j.molimm.2011.11.008

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  20 in total

1.  How does batf3 determine dendritic cell development?

Authors:  Ken Shortman
Journal:  Immunol Cell Biol       Date:  2015-08-25       Impact factor: 5.126

2.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  RNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells.

Authors:  Kirsteen M Tullett; Peck Szee Tan; Hae-Young Park; Ralf B Schittenhelm; Nicole Michael; Rong Li; Antonia N Policheni; Emily Gruber; Cheng Huang; Alex J Fulcher; Jillian C Danne; Peter E Czabotar; Linda M Wakim; Justine D Mintern; Georg Ramm; Kristen J Radford; Irina Caminschi; Meredith O'Keeffe; Jose A Villadangos; Mark D Wright; Marnie E Blewitt; William R Heath; Ken Shortman; Anthony W Purcell; Nicos A Nicola; Jian-Guo Zhang; Mireille H Lahoud
Journal:  Elife       Date:  2020-12-02       Impact factor: 8.140

Review 4.  Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.

Authors:  Craig P Chappell; Natalia V Giltiay; Christiane Dresch; Edward A Clark
Journal:  Int Immunol       Date:  2013-11-27       Impact factor: 4.823

5.  Development of a Novel CD4+ TCR Transgenic Line That Reveals a Dominant Role for CD8+ Dendritic Cells and CD40 Signaling in the Generation of Helper and CTL Responses to Blood-Stage Malaria.

Authors:  Daniel Fernandez-Ruiz; Lei Shong Lau; Nazanin Ghazanfari; Claerwen M Jones; Wei Yi Ng; Gayle M Davey; Dorothee Berthold; Lauren Holz; Yu Kato; Matthias H Enders; Ganchimeg Bayarsaikhan; Sanne H Hendriks; Lianne I M Lansink; Jessica A Engel; Megan S F Soon; Kylie R James; Anton Cozijnsen; Vanessa Mollard; Alessandro D Uboldi; Christopher J Tonkin; Tania F de Koning-Ward; Paul R Gilson; Tsuneyasu Kaisho; Ashraful Haque; Brendan S Crabb; Francis R Carbone; Geoffrey I McFadden; William R Heath
Journal:  J Immunol       Date:  2017-10-30       Impact factor: 5.422

Review 6.  New generation of dendritic cell vaccines.

Authors:  Kristen J Radford; Irina Caminschi
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

7.  Display of Native Antigen on cDC1 That Have Spatial Access to Both T and B Cells Underlies Efficient Humoral Vaccination.

Authors:  Yu Kato; Thiago M Steiner; Hae-Young Park; Rohan O Hitchcock; Ali Zaid; Jyh Liang Hor; Sapna Devi; Gayle M Davey; David Vremec; Kirsteen M Tullett; Peck S Tan; Fatma Ahmet; Scott N Mueller; Sylvie Alonso; David M Tarlinton; Hidde L Ploegh; Tsuneyasu Kaisho; Lynette Beattie; Jonathan H Manton; Daniel Fernandez-Ruiz; Ken Shortman; Mireille H Lahoud; William R Heath; Irina Caminschi
Journal:  J Immunol       Date:  2020-08-24       Impact factor: 5.422

Review 8.  Dendritic-cell-based therapeutic cancer vaccines.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.

Authors:  Bijun Zeng; Anton Pj Middelberg; Adrian Gemiarto; Kelli MacDonald; Alan G Baxter; Meghna Talekar; Davide Moi; Kirsteen M Tullett; Irina Caminschi; Mireille H Lahoud; Roberta Mazzieri; Riccardo Dolcetti; Ranjeny Thomas
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

Review 10.  Human dendritic cell subsets in vaccination.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Curr Opin Immunol       Date:  2013-05-30       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.